Andrews MC - Search Results

1

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.

Da Gama Duarte J, Parakh S, Andrews MC, Woods K, Pasam A, Tutuka C, Ostrouska S, Blackburn JM, Behren A, Cebon J. Da Gama Duarte J, et al. Among authors: andrews mc. Front Immunol. 2018 Mar 2;9:411. doi: 10.3389/fimmu.2018.00411. eCollection 2018. Front Immunol. 2018. PMID: 29552014 Free PMC article. Clinical Trial.

2

Human perforin mutations and susceptibility to multiple primary cancers.

Trapani JA, Thia KY, Andrews M, Davis ID, Gedye C, Parente P, Svobodova S, Chia J, Browne K, Campbell IG, Phillips WA, Voskoboinik I, Cebon JS. Trapani JA, et al. Oncoimmunology. 2013 Apr 1;2(4):e24185. doi: 10.4161/onci.24185. Oncoimmunology. 2013. PMID: 23734337 Free PMC article.

3

BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition.

Andrews MC, Behren A, Chionh F, Mariadason J, Vella LJ, Do H, Dobrovic A, Tebbutt N, Cebon J. Andrews MC, et al. J Clin Oncol. 2013 Dec 10;31(35):e448-51. doi: 10.1200/JCO.2013.50.4118. Epub 2013 Nov 4. J Clin Oncol. 2013. PMID: 24190114 No abstract available.

4

A single-centre experience of patients with metastatic melanoma enrolled in a dabrafenib named patient programme.

Lau DK, Andrews MC, Turner N, Azad AA, Davis ID, Cebon JS. Lau DK, et al. Among authors: andrews mc. Melanoma Res. 2014 Apr;24(2):144-9. doi: 10.1097/CMR.0000000000000036. Melanoma Res. 2014. PMID: 24463460

5

MEK inhibition, alone or in combination with BRAF inhibition, affects multiple functions of isolated normal human lymphocytes and dendritic cells.

Vella LJ, Pasam A, Dimopoulos N, Andrews M, Knights A, Puaux AL, Louahed J, Chen W, Woods K, Cebon JS. Vella LJ, et al. Cancer Immunol Res. 2014 Apr;2(4):351-60. doi: 10.1158/2326-6066.CIR-13-0181. Epub 2014 Jan 17. Cancer Immunol Res. 2014. PMID: 24764582

6

Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatment.

Vella LJ, Andrews MC, Behren A, Cebon J, Woods K. Vella LJ, et al. Among authors: andrews mc. Expert Rev Clin Immunol. 2014 Aug;10(8):1107-23. doi: 10.1586/1744666X.2014.929943. Epub 2014 Jun 17. Expert Rev Clin Immunol. 2014. PMID: 24939732 Review.

7

Evolving role of tumor antigens for future melanoma therapies.

Andrews MC, Woods K, Cebon J, Behren A. Andrews MC, et al. Future Oncol. 2014 Jun;10(8):1457-68. doi: 10.2217/fon.14.84. Future Oncol. 2014. PMID: 25052755 Review.

8

Response to MAPK pathway inhibitors in BRAF V600M-mutated metastatic melanoma.

Parakh S, Murphy C, Lau D, Cebon JS, Andrews MC. Parakh S, et al. Among authors: andrews mc. J Clin Pharm Ther. 2015 Feb;40(1):121-3. doi: 10.1111/jcpt.12229. Epub 2014 Nov 10. J Clin Pharm Ther. 2015. PMID: 25382067

9

Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cells.

Woods K, Pasam A, Jayachandran A, Andrews MC, Cebon J. Woods K, et al. Among authors: andrews mc. Front Oncol. 2014 Dec 17;4:367. doi: 10.3389/fonc.2014.00367. eCollection 2014. Front Oncol. 2014. PMID: 25566505 Free PMC article. Review.

10

The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.

Vella LJ, Andrews MC, Pasam A, Woods K, Behren A, Cebon JS. Vella LJ, et al. Among authors: andrews mc. Oncoimmunology. 2014 Jul 3;3(7):e946367. doi: 10.4161/21624011.2014.946367. eCollection 2014. Oncoimmunology. 2014. PMID: 25610732 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

110 results

Search Page